Cargando…

Pore forming–mediated intracellular protein delivery for enhanced cancer immunotherapy

Directly delivering therapeutic proteins to their intracellular targets remains a great challenge. Here, we apply CD8(+) T cells to form pores on the tumor cells’ plasma membranes, enabling perfusion of ribonuclease A (RNase A) and granzyme B into cells, therefore effectively inducing tumor apoptosi...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhou, Zhanwei, Yang, Ruoxi, Dong, Jingwen, Di, Yongxiang, Yang, Ying, Huang, Ying, Yang, Xue, Liu, Wei, Wang, Jinqiang, Liu, Peifeng, Gu, Zhen, Sun, Minjie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for the Advancement of Science 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9674288/
https://www.ncbi.nlm.nih.gov/pubmed/36399575
http://dx.doi.org/10.1126/sciadv.abq4659
_version_ 1784833124639703040
author Zhou, Zhanwei
Yang, Ruoxi
Dong, Jingwen
Di, Yongxiang
Yang, Ying
Huang, Ying
Yang, Xue
Liu, Wei
Wang, Jinqiang
Liu, Peifeng
Gu, Zhen
Sun, Minjie
author_facet Zhou, Zhanwei
Yang, Ruoxi
Dong, Jingwen
Di, Yongxiang
Yang, Ying
Huang, Ying
Yang, Xue
Liu, Wei
Wang, Jinqiang
Liu, Peifeng
Gu, Zhen
Sun, Minjie
author_sort Zhou, Zhanwei
collection PubMed
description Directly delivering therapeutic proteins to their intracellular targets remains a great challenge. Here, we apply CD8(+) T cells to form pores on the tumor cells’ plasma membranes, enabling perfusion of ribonuclease A (RNase A) and granzyme B into cells, therefore effectively inducing tumor apoptosis and pyroptosis by activating caspase 3 and gasdermin E pathways to potentiate the CD8(+) T cell–mediated immunotherapy. Then, RNase A, programmed cell death ligand 1 antibody, and a photothermal agent were further loaded into an injectable hydrogel to treat the low immunogenic murine breast cancer. Notably, three courses of laser irradiation induced efficient cell apoptosis and immune activation, resulting in a notable therapeutic efficacy that 75% of the tumors were ablated without relapse.
format Online
Article
Text
id pubmed-9674288
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher American Association for the Advancement of Science
record_format MEDLINE/PubMed
spelling pubmed-96742882022-11-29 Pore forming–mediated intracellular protein delivery for enhanced cancer immunotherapy Zhou, Zhanwei Yang, Ruoxi Dong, Jingwen Di, Yongxiang Yang, Ying Huang, Ying Yang, Xue Liu, Wei Wang, Jinqiang Liu, Peifeng Gu, Zhen Sun, Minjie Sci Adv Biomedicine and Life Sciences Directly delivering therapeutic proteins to their intracellular targets remains a great challenge. Here, we apply CD8(+) T cells to form pores on the tumor cells’ plasma membranes, enabling perfusion of ribonuclease A (RNase A) and granzyme B into cells, therefore effectively inducing tumor apoptosis and pyroptosis by activating caspase 3 and gasdermin E pathways to potentiate the CD8(+) T cell–mediated immunotherapy. Then, RNase A, programmed cell death ligand 1 antibody, and a photothermal agent were further loaded into an injectable hydrogel to treat the low immunogenic murine breast cancer. Notably, three courses of laser irradiation induced efficient cell apoptosis and immune activation, resulting in a notable therapeutic efficacy that 75% of the tumors were ablated without relapse. American Association for the Advancement of Science 2022-11-18 /pmc/articles/PMC9674288/ /pubmed/36399575 http://dx.doi.org/10.1126/sciadv.abq4659 Text en Copyright © 2022 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works. Distributed under a Creative Commons Attribution NonCommercial License 4.0 (CC BY-NC). https://creativecommons.org/licenses/by-nc/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial license (https://creativecommons.org/licenses/by-nc/4.0/) , which permits use, distribution, and reproduction in any medium, so long as the resultant use is not for commercial advantage and provided the original work is properly cited.
spellingShingle Biomedicine and Life Sciences
Zhou, Zhanwei
Yang, Ruoxi
Dong, Jingwen
Di, Yongxiang
Yang, Ying
Huang, Ying
Yang, Xue
Liu, Wei
Wang, Jinqiang
Liu, Peifeng
Gu, Zhen
Sun, Minjie
Pore forming–mediated intracellular protein delivery for enhanced cancer immunotherapy
title Pore forming–mediated intracellular protein delivery for enhanced cancer immunotherapy
title_full Pore forming–mediated intracellular protein delivery for enhanced cancer immunotherapy
title_fullStr Pore forming–mediated intracellular protein delivery for enhanced cancer immunotherapy
title_full_unstemmed Pore forming–mediated intracellular protein delivery for enhanced cancer immunotherapy
title_short Pore forming–mediated intracellular protein delivery for enhanced cancer immunotherapy
title_sort pore forming–mediated intracellular protein delivery for enhanced cancer immunotherapy
topic Biomedicine and Life Sciences
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9674288/
https://www.ncbi.nlm.nih.gov/pubmed/36399575
http://dx.doi.org/10.1126/sciadv.abq4659
work_keys_str_mv AT zhouzhanwei poreformingmediatedintracellularproteindeliveryforenhancedcancerimmunotherapy
AT yangruoxi poreformingmediatedintracellularproteindeliveryforenhancedcancerimmunotherapy
AT dongjingwen poreformingmediatedintracellularproteindeliveryforenhancedcancerimmunotherapy
AT diyongxiang poreformingmediatedintracellularproteindeliveryforenhancedcancerimmunotherapy
AT yangying poreformingmediatedintracellularproteindeliveryforenhancedcancerimmunotherapy
AT huangying poreformingmediatedintracellularproteindeliveryforenhancedcancerimmunotherapy
AT yangxue poreformingmediatedintracellularproteindeliveryforenhancedcancerimmunotherapy
AT liuwei poreformingmediatedintracellularproteindeliveryforenhancedcancerimmunotherapy
AT wangjinqiang poreformingmediatedintracellularproteindeliveryforenhancedcancerimmunotherapy
AT liupeifeng poreformingmediatedintracellularproteindeliveryforenhancedcancerimmunotherapy
AT guzhen poreformingmediatedintracellularproteindeliveryforenhancedcancerimmunotherapy
AT sunminjie poreformingmediatedintracellularproteindeliveryforenhancedcancerimmunotherapy